Physician profile
Joseph E Allen
NPI 1285720011
$4,464.05
in general payments reported to CMS, 2019-2025
31 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $377 · 2021: $936 · 2022: $687 · 2023: $638 · 2024: $846 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $805.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $766.31 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $565.72 | 2021-2023 | Qulipta, Ubrelvy |
| Gilead Sciences, INC. | $467.28 | 2019-2025 | |
| Pfizer INC. | $302.48 | 2019-2024 | |
| Lilly USA, LLC | $297.39 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $167.11 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Emd Serono, INC. | $142.66 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.84 | 2022-2024 | Xifaxan |
| Allergan, INC. | $114.21 | 2020 | |
| Eisai INC. | $71.82 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.40 | 2021 | |
| Tempus Ai, INC | $55.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $54.59 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $49.07 | 2023-2024 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $48.53 | 2024 | |
| Horizon Therapeutics Plc | $42.93 | 2020-2021 | |
| Nevro Corp. | $37.99 | 2023-2024 | Senza |
| Phathom Pharmaceuticals, INC. | $34.98 | 2024 | Voquezna |
| Neo Spine USA, INC. | $33.65 | 2024 | Neo Pedicle Screw System |
| Abbott Laboratories | $33.34 | 2021-2022 | |
| Balt USA, LLC | $30.46 | 2025 | Prestige Coil System |
| Paratek Pharmaceuticals, INC. | $20.52 | 2025 | Nuzyra |
| Exact Sciences Corporation | $19.58 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $19.39 | 2024 | (Ck7) Extended Holter |
| Bausch Health US, LLC | $18.46 | 2020 | |
| Merck Sharp & Dohme LLC | $18.38 | 2019 | |
| Almatica Pharma LLC | $16.64 | 2025 | Teriparatide, Loreev Xr |
| Alkermes, INC. | $15.88 | 2019 | |
| Zyla Life Sciences, INC. | $15.60 | 2019 | |
| Cipher Pharmaceuticals US LLC | $13.96 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.